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GlycosphingolipidGangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key
regulatory role in a diverse array of cellular processes, including receptor-associated signalling.
Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological
changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resis-
tance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-
induced perturbations in metabolic function, including impaired insulin action. By doing so, we
highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-
related metabolic disorders.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gangliosides constitute one class of glycosphingolipid which
contain one or more sialic acid residues, and are known to reside
within the plasma membrane where they can modulate receptor-
mediated signal transduction [1–4]. Importantly, there has been
recent growing interest regarding ganglioside mediated regulation
of energy homeostasis and metabolic function. Herein, we discuss
experimental evidence supporting the involvement of one particu-
lar ganglioside, known as GM3 (monosialodihexosylganglioside),
in the modulation of processes that fulfil important metabolic
roles.
1.1. Glycosphingolipid biosynthesis and metabolism
The biosynthesis of most glycosphingolipids derives from cera-
mide, a key lipid precursor formed by its de novo synthesis or from
the hydrolysis of complex sphingolipids and sphingomyelin (see
Fig. 1). Ceramide de novo synthesis is initiated by the generation
of 3-ketosphinganine from its precursors palmitoyl-CoA and serine
by the enzyme Serine Palmitoyl Transferase (SPT) [5]. Glucosylce-
ramide is then formed via glucosylation of ceramide by glucosylce-
ramide synthase (GCS) [6,7]. Glucosylceramide is subsequentlyconverted to lactosylceramide via the (1-4)-b linkage of galactose
[8]. Gangliosides can then be produced from lactosylceramide
through the addition of N-acetylneuraminic acid (sialic acid) units
(Fig. 1). This sialylation is catalysed by sialyl transferase enzymes,
and the particular isoform(s) involved determines the specific gan-
glioside produced. For example, the sialyl transferase GM3 syn-
thase (also known as lactosylceramide a-2,3-sialyltransferase)
catalyses the addition of a sialic acid group onto the terminal galac-
tose group of lactosylceramide to generate GM3 (Siaa2-3Galb1-4
Glcb1-1Cer), the simplest and most widely distributed ganglioside
(see Fig. 1). Notably, GM3 acts as a metabolic precursor for the for-
mation of more complex gangliosides and is particularly abundant
in liver and adipose tissue, wherein it comprises between 80% and
90% of total ganglioside content [9–12].
In addition to those pathways implicated in their synthesis,
gangliosides can also be degraded through hydrolytic cleavage of
sialic acid chains by the action of sialidase enzymes present within
lysosomal and plasma membranes [13,14]. Notably, four types of
human sialidases have been identified to date, each with different
subcellular locations and substrate specificities [13,15]. For exam-
ple, NEU3 sialidase which resides within the plasma membrane
preferentially targets GM3 for hydrolysis. Following removal of sia-
lic acid group(s), gangliosides are converted into glycosphin-
golipids which can be further broken down by lysosomal
hydrolases.
Fig. 1. Summary of pathways leading to the formation of GM3 via de novo synthesis of ceramide. CS, ceramide synthase; DS, desaturase; GCS, glucosylceramide synthase; LS,
lactosylceramide synthase; NDR, NADPH-dependent reductase.
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Various strategies have been used to manipulate cellular levels
of GM3, which can be monitored and/or detected using thin layer
and high pressure liquid chromatography, as well as immunostain-
ing. A common approach used to reduce GM3 biosynthesis is
through pharmacological inhibition. Although a specific inhibitor
of GM3 synthase has yet to be developed, GM3 levels can be
reduced following application of glucosylceramide synthase inhi-
bitors such as D-1-threo-1-phenyl-2-decanoylamino-3-morpho
lino-1-propanol (PDMP), D-1-threo-1-phenyl-2-palmitoylamino-3
-pyrolidno-1-propanol (PPPP), Genz-123346 and N-(50-adaman
tane-10-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM)
[2,16–20] (Fig. 2). Alternatively, RNA interference-mediated gene
silencing of GM3 synthase has been used to explore the role of
GM3 in cell death and proliferation [21,22]. Alternatively, as well
as targeting enzymes involved in GM3 synthesis, GM3 abundance
can also be altered by manipulating the expression and/or activity
of NEU3 sialidase. Indeed, repressing sialidase expression and/or
activity through targeted RNA interference has been associated
with increased cellular GM3 accumulation [23].
Allied to these strategies, transgenic and gene knockout mouse
models have also been generated which either express or are defi-
cient for GM3 synthesising or degrading enzymes [24]. Notable
examples include mice deficient for GM3 synthase which lackthe capacity to synthesise GM3 [25], or transgenic mice expressing
NEU3 sialidase which display reduced tissue and circulating levels
of GM3 [26].
1.3. GM3 cellular localisation
Lipid rafts are membrane microdomains which are enriched in
cholesterol and various sphingolipids, as well as certain proteins
adhered by glycosyl-phosphatidylinositol (GPI) anchors [27]. Cave-
olae are specialised lipid raft domains which form small invagina-
tions of the plasma membrane, facilitated by the presence of a
caveolin protein coat [27,28]. Caveolin-1, -2 and-3 isoforms are
integral membrane proteins which play key roles in the formation
and function of caveolin enriched microdomains (CEMs). Notably,
many lipid rafts including caveolin enriched membrane microdo-
mains (CEMs) are not readily solubilised by detergent treatment
due to the high abundance of sphingolipids and cholesterol. Due
to this, lipid raft components can often be isolated from cells using
non-ionic detergents such as Triton-X100 at cold temperatures,
which act to solubilise the bilayer whilst leaving many compo-
nents of detergent resistant membrane microdomain (DRM) frac-
tions intact. Indeed, such DRM fractions are widely
acknowledged to be the biochemical equivalent of lipid rafts and
CEMs. Studies performed using both biochemical and microscopic
techniques have identified the presence of GM3 within CEMs as
Fig. 2. Structures of commonly used glucosylceramide synthase inhibitors. D-threo-PDMP, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol; Genz-123346,
N-[(1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]nonanamide; AMP-DNM, N-(50-adamantane-10-yl-methoxy)-pentyl-1-
deoxynojirimycin.
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also been implicated in promoting the subcellular redistribution of
key CEM components involved in coordinating signal transduction,
including caveolin isoforms [29,30].
2. The role of GM3 in obesity-induced insulin resistance
2.1. Obesity related factors regulating insulin action
Initiation of insulin-induced signalling is triggered from the
activated insulin receptor kinase which can bind and regulate a
number a downstream intracellular targets, including the insulin
receptor substrate (IRS) family of proteins and phosphatidylinosi-
tol 3 kinase (PI3K) [31,32]. The subsequent PI3K-mediated genera-
tion of phosphatidylinositol-(3,4,5)-triphosphate (PIP3) promotes
translocation of protein kinase B (PKB) (also known as Akt) to
the plasma membrane where it undergoes phosphorylation by
upstream kinases at its two key regulatory sites, Thr308 and
Ser473 (of PKBa/Akt1), respectively. In turn, active PKB/Akt medi-
ates phosphorylation of downstream effector proteins that are
involved in coordinating the metabolic effects of insulin. For exam-
ple, PKB/Akt acts to stimulate glycogen synthesis and GLUT-
dependent glucose uptake by phosphorylating and inactivating
GSK3 (Glycogen Synthase Kinase 3) and the Rab GTPase-
activating protein AS160 (Akt substrate of 160kDa), respectively
[33,34]. Proper regulation of these cellular processes is therefore
crucial for maintaining glucose homeostasis by controlling glucose
storage and utilisation [35,36]. Consequently, any condition which
impairs insulin action can lead to the dysregulation of systemic
glucose homeostasis. In particular, a number of obesity-related fac-
tors such as raised circulating levels of non-esterified free fatty
acids (NEFAs) (e.g. palmitate C16:0) or pro-inflammatory cytokines
(e.g. TNFa) have been implicated in mediating the development of
insulin resistance, however, the exact molecular mechanisms
underlying their insulin-desensitising actions are not yet fully
understood and are likely to be multifactorial in nature [36–40].
2.2. GM3 mediated regulation of insulin signalling
One of the earliest reports linking GM3 with the development of
insulin resistance came in a study by Tagami and colleagues who
first demonstrated that TNF-a induced insulin desensitisation in
3T3-L1 adipocytes concurred with increased cellular GM3
abundance [41]. Importantly, pharmacological inhibition of GM3
synthesis using glucosylceramide synthase inhibitors such as
AMP-DNM and D-PDMP has been shown to prevent TNF-a induced
insulin resistance [1,41]. In accord with this, exposure of 3T3-L1
adipocytes to exogenous GM3 was found to attenuate insulin-
induced tyrosine phosphorylation of the insulin receptor and that
of IRS-1, concomitant with impaired insulin-stimulated glucose
uptake [41].Notably, insulin receptors are known to localise within
caveolin-enriched membrane microdomains (CEMs), whilst dis-
rupting the integrity of CEMs has been shown to perturb signal
transduction from the insulin receptor in response to ligand bind-
ing [42]. For example, pharmacological depletion of cellular choles-
terol using b-cyclodextrin, which promotes a loss in caveolar
integrity and function, has been reported to impair insulin induced
signalling in 3T3-L1 adipocytes [42]. Therefore, CEM localisation
facilitates the ability of the insulin receptor to initiate downstream
signalling effectively. In accordance with this, Kabayama and co-
workers previously demonstrated that exposure of 3T3-L1 adipo-
cytes to TNF-a results in the cellular accumulation of GM3, as well
as increased GM3 content within detergent resistant membranes
(DRMs) isolated in low density fractions [43]. Intriguingly, this
increase in GM3 abundance concurred with a marked reduction
in insulin receptor protein expression within DRMs, thereby indi-
cating dissociation of the insulin receptor from DRMs under condi-
tions of raised GM3 abundance. Allied to this, blocking GM3
synthesis in 3T3-L1 adipocytes using d-PDMP has been shown to
counter-modulate the reduction in insulin receptor protein expres-
sion within DRMs and associated loss in insulin sensitivity follow-
ing exposure to TNF-a [43].
Importantly, these findings indicate that TNF-a induced insulin
resistance may be due, at least in part, to the altered composition
of DRMs in which key insulin signalling components reside. More
specifically, this may involve altering direct interactions between
the insulin receptor and caveolin isoforms within caveolin-
enriched DRMs [44,45]. For example, under normal conditions in
3T3-L1 adipocytes, the insulin receptor forms a direct association
with caveolin-1 which is important for effective insulin-induced
signalling [1]. However, it has been proposed that GM3 disrupts
the interaction between the insulin receptor and caveolin-1, result-
ing in the increased mobility of insulin receptors and their subse-
quent dissociation from caveolin-enriched DRMs [1,2,44,45].
Furthermore, because GM3 itself has been shown to directly asso-
ciate with the insulin receptor, independently of caveolin-1, the
ganglioside may promote insulin resistance by competing with
caveolin-1 for binding to the insulin receptor [1]. Indeed, this
may arise due to the presence of a specific lysine residue (Lys
944) located within insulin receptor b subunit which has been sug-
gested to mediate its interaction with GM3 [1]. Consistent with
these findings, work by Sekimoto and colleagues demonstrated
that the dissociation of the insulin receptor from caveolin-1
enriched DRMs in response to TNF-a provision can be largely pre-
vented by co-treatment with D-PDMP, concomitant with the
restoration of insulin induced tyrosine phosphorylation [2].
In addition to its reported ability to modulate insulin receptor
localisation, GM3 may also repress insulin signalling through
inhibiting IRS-1 function. Notably, serine phosphorylation of IRS-1
acts to impair its interaction with the insulin receptor, thereby
reducing its ability to undergo insulin-induced tyrosine phosphory-
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synthesis has been shown to reduce serine phosphorylation of IRS-
1 in response to TNF-a treatment, concomitantwith improved insu-
lin sensitivity [41]. Therefore, multiple mechanisms may underlie
the development of insulin resistance in response to the accumula-
tion of GM3.
2.3. Involvement of GM3 in obesity associated insulin resistance
Suppressing GM3 production has also been demonstrated to
improve insulin sensitivity in various rodent models of obesity
and type 2 diabetes. For example, Yamashita and co-workers first
demonstrated that mice deficient in GM3 synthase display height-
ened insulin sensitivity (as evidenced by enhanced insulin receptor
tyrosine phosphorylation in skeletal muscle) as well as improved
glucose tolerance [25]. Moreover, GM3 synthase knockout mice
are protected from high fat diet-induced insulin resistance and
impaired glucose tolerance, as well as displaying an anti-
inflammatory phenotype in adipose tissue [25,47]. Consistent with
this, adenoviral-mediated expression of NEU3 sialidase in livers of
high fat fed C57BL/6 mice and insulin resistant KKAy mice was
similarly shown to improve insulin sensitivity and glucose toler-
ance [26]. This was demonstrated by enhanced insulin-
stimulated tyrosine phosphorylation of the insulin receptor and
of IRS-1, which coincided with reduced hepatic GM3 content in
the livers of NEU3 expressing mice [26].
In accord with these findings, inhibiting GM3 synthesis by phar-
macological means has similarly been shown to improve glucose
homeostasis and insulin sensitivity in vivo. For example, adminis-
tering the glucosylceramide synthase inhibitor Genz-123346 has
been reported to improve glucose tolerance in Zucker diabetic fatty
rats, as well as heighten insulin sensitivity within skeletal muscle
[20]. In addition, pharmacological inhibition of glucosylceramide
(and therefore GM3) biosynthesis by AMP-DNM was found to
enhance insulin action in adipocytes isolated from leptin deficient
ob/ob obese mice, concomitant with reduced inflammation within
fat tissue [48]. In separate studies, treatment of ob/ob mice with
AMP-DNM similarly improved oral glucose tolerance and insulin
sensitivity in liver and skeletal muscle, which concurred with the
normalisation of circulating glucose and insulin levels [19,49].
It should be stressed, however, that the ability of GM3 to mod-
ulate insulin action may be tissue and/or cell type dependent. For
example, a recent study by Chavez and colleagues demonstrated
that whilst inhibition of enzymes required for de novo ceramide
synthesis (e.g. through application of the SPT inhibitor myriocin)
negated palmitate-induced insulin resistance in cultured muscle
cells, a similar insulin sensitising effect was not observed using
pharmacological agents that inhibit glucosylceramide synthase
(and therefore GM3 synthesis) [50]. In contrast, addition of exoge-
nous ganglioside GM3 or overexpression of glucosylceramide syn-
thase in adipocytes, but not in myotubes, led to suppressed insulin
action [50]. Therefore, these findings indicate that GM3 may play a
more prominent role in promoting insulin resistance within cer-
tain tissues, for example adipose tissue. However, despite these
findings in vitro, a role for GM3 in the development of insulin resis-
tance in other tissues such as skeletal muscle, particularly in vivo,
cannot be ruled out. Indeed, enhanced insulin sensitivity and glu-
cose uptake has been reported in skeletal muscle of GM3 synthase
deficient mice [25]. Therefore, further work will be required to
determine the regulatory function(s) of GM3 in different tissues,
particularly in response to various pathological conditions (e.g.
obesity and/or ageing).
One characteristic feature of obesity includes raised circulating
levels of non-esterified free fatty acids. Importantly, long chain sat-
urated fatty acids such as palmitate (C16:0) are potent inducers ofinsulin resistance. In contrast, unsaturated fatty acids are able to
protect against the detrimental insulin desensitising and pro-
inflammatory effects of palmitate [51,52]. Interestingly, we have
recently reported that saturated and unsaturated fatty acids can
differentially modulate NEU3 mRNA and protein expression in
rat L6 myotubes [53]. Specifically, the ability of the saturated fatty
acid palmitate (C16:0) to promote insulin resistance in L6 myo-
tubes coincided with a marked reduction in NEU3 mRNA and pro-
tein abundance [53]. Strikingly, co-incubation with the
unsaturated fatty acid oleate (C18:1) completely negated the loss
in insulin action and reduction in NEU3 abundance (mRNA and
protein) in response to palmitate provision [53]. Notably, palmitate
induced repression of NEU3 was shown to be mediated through a
mechanism involving the generation of ceramide and its subse-
quent inhibition of PKB. Moreover, the ability of oleate alone to
enhance insulin sensitivity in L6 myotubes concurred with
increased NEU3 protein. Together, these findings support a positive
role for NEU3 sialidase in facilitating insulin signal transduction,
potentially through its reported ability to co-localise with caveolin
proteins in membrane microdomains [54,55].
However, it should be highlighted that forced NEU3 expression
has been associated with reduced insulin sensitivity. In particular,
an independent study by Sasaki and colleagues reported diabetic
symptoms in transgenic mice overexpressing NEU3 sialidase,
which were found to display raised plasma insulin levels, and
reduced insulin-stimulated phosphorylation of the insulin receptor
and IRS-1 in liver [56]. Furthermore, the authors of the same study
also demonstrated that transient transfection of wild type NEU3
significantly impaired insulin action in L6 myocytes.
One possible explanation for these disparate findings may be
due to differences in the experimental approaches adopted. For
example, Yoshizumi and colleagues specifically expressed NEU3
in liver using adenoviral vectors whilst the study by Sasaki utilised
NEU3 transgenic mice [26,56]. Furthermore, Yoshizumi and co-
workers examined the metabolic effects of forced NEU3 expression
in high fat fed mice, whereas the Sasaki led study did not utilise a
model of insulin resistance pre-induced by dietary or genetic
means. In addition, it is possible that overexpressing NEU3 at sup-
raphysiological levels may lead to the aberrant accumulation of
desialylation and/or hydrolytic products (e.g. ceramides) which
have been implicated in promoting insulin resistance [26]. There-
fore, these findings suggest that NEU3, potentially through its abil-
ity to modulate GM3 expression, may act to regulate peripheral
insulin sensitivity.
3. Gangliosides and pancreatic function
The pancreas functions as a key site for the production and
secretion of insulin in response to elevated blood glucose. Conse-
quently, impaired pancreatic beta cell function has been proposed
to be a major contributing factor in the development of Type 2 dia-
betes [57]. Indeed, chronic glucose and fatty acid oversupply, as
observed in the obese state, can trigger and/or perpetuate pancre-
atic b-cell dysfunction and failure [57,58]. In accord with this, sat-
urated fatty acids such as palmitate have been shown to induce
beta cell dysfunction and apoptosis, as well as decrease beta cell
mass [59–61]. For example, this may be mediated through the pro-
duction of ceramides and/or derived products, which have been
implicated in promoting beta cell apoptosis [62,63].
A number of gangliosides including GM3 have been detected
within pancreatic tissue [64,65]. Interestingly, pancreatic injury
is associated with increased GM3 abundance and a corresponding
loss in c-series gangliosides (e.g. GT3, GT2, GQ1c) in STZ induced
diabetic rats [64]. In accord with this, improvements in glucose tol-
erance and insulin sensitivity in obese Zucker diabetic fatty rats
Fig. 3. Possible mechanisms involved in GM3-mediated insulin resistance. Obesity related increases in circulating saturated fatty acids (FAs) such as palmitate (C16:0) and/or
pro-inflammatory cytokines (e.g. TNF-a) have been reported to stimulate production of GM3 (via increased GM3 synthase activity) at the plasma membrane (A). Because
GM3 has been shown to compete with caveolin proteins for the binding of the insulin receptor, the resulting increase in GM3 abundance may promote the redistribution of
insulin receptors away from caveolin-enriched membrane microdomains (CEMs), which in turn may reduce their signalling efficiency (B). Alternatively, GM3 may act to
stimulate serine phosphorylation of IRS-1 thereby impairing its ability to transduce receptor induced signalling (C). Notably, it has been shown that both obesity and the
insulin-desensitising action of palmitate are associated with reduced NEU3 sialidase expression (D). This would be predicted to further contribute to an elevation in GM3
abundance through suppressing its hydrolysis and degradation.
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have been shown to coincide with the preservation of pancreatic
beta cell function and insulin secretion [20]. Furthermore, trans-
genic mice overexpressing NEU3 sialidase display increased pan-
creatic islet cell size and elevated circulating levels of insulin,
indicative of enhanced pancreatic function [56]. Therefore, emerg-
ing evidence suggests that gangliosides such as GM3 may play a
key role in modulating pancreatic function and therefore insulin
production. However, further work will be required to establish
which specific ganglioside species are involved in the onset of obe-
sity and/or diabetes associated pancreatic dysfunction.
4. Gangliosides in human metabolic disease
Gangliosides have been implicated in the development of vari-
ous human pathologies including lysosomal storage disorders and
Alzheimer’s disease [66]. Importantly, emerging evidence has also
linked the accumulation of gangliosides such as GM3 with the
development of human metabolic disorders. For example, elevated
serum levels of GM3 molecular species have been reported in
hyperglycaemic and hyperlipidaemic subjects, as well as in type
2 diabetic patients [67,68]. Furthermore, individuals with Gaucher
disease, a genetic disorder characterised by a deficiency of gluco-
cerebrosidase (an enzyme which functions to hydrolyse glucosyl-
ceramide), show an increased propensity for developing insulin
resistance concomitant with raised plasma GM3 concentrations
[69]. Indeed, these findings suggest that dysregulation of GM3 syn-
thesis and/or metabolism may contribute towards impaired glu-
cose and lipid homeostasis in humans. Moreover, it is possible
that circulating GM3 and/or sialidase (NEU3) activity may be used
as a potential biomarker for insulin resistance.
5. Conclusions
To conclude, there is growing appreciation that GM3 plays a key
role in modulating insulin sensitivity and energy homeostasis.Collectively, the evidence presented in this review indicates that
GM3 acts to convey detrimental effects upon metabolic function
for example, by negatively modulating insulin signalling (see
Fig. 3). Consequently, these studies highlight the potential benefits
of therapies aimed at targeting GM3 biosynthesis in order to coun-
teract obesity-induced metabolic perturbations, as well as amelio-
rating other manifestations of metabolic syndrome such as fatty
liver disease (see review by Aerts et al. [70]).
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